Hydroxymethylglutaryl-CoA Reductase Inhibitors

"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.

Descriptor ID	D019161
MeSH Number(s)	D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
Concept/Terms	Hydroxymethylglutaryl-CoA Reductase Inhibitors Hydroxymethylglutaryl-CoA Reductase Inhibitors Hydroxymethylglutaryl CoA Reductase Inhibitors Inhibitors, Hydroxymethylglutaryl-CoA Reductase Reductase Inhibitors, Hydroxymethylglutaryl-CoA Inhibitors, HMG-CoA Reductase Inhibitors, HMG CoA Reductase Reductase Inhibitors, HMG-CoA HMG-CoA Reductase Inhibitors HMG CoA Reductase Inhibitors Statins, HMG-CoA HMG-CoA Statins Statins, HMG CoA Inhibitors, Hydroxymethylglutaryl-CoA Hydroxymethylglutaryl-CoA Inhibitors Inhibitors, Hydroxymethylglutaryl CoA Statins Inhibitors, Hydroxymethylglutaryl-Coenzyme A Hydroxymethylglutaryl-Coenzyme A Inhibitors Inhibitors, Hydroxymethylglutaryl Coenzyme A

Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Antimetabolites [D27.505.519.186]
Hypolipidemic Agents [D27.505.519.186.071]
Anticholesteremic Agents [D27.505.519.186.071.202]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.186.071.202.370]
Enzyme Inhibitors [D27.505.519.389]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.389.370]
Therapeutic Uses [D27.505.954]
Lipid Regulating Agents [D27.505.954.557]
Hypolipidemic Agents [D27.505.954.557.500]
Anticholesteremic Agents [D27.505.954.557.500.202]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.954.557.500.202.370]

Below are MeSH descriptors whose meaning is related to "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 146 publications over 23 distinct years, with a maximum of 12 publications in 2012 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	3	1	4
2003	3	2	5
2004	6	2	8
2005	6	0	6
2006	4	3	7
2007	4	4	8
2008	5	2	7
2009	5	0	5
2010	7	2	9
2011	5	5	10
2012	5	7	12
2013	5	2	7
2014	6	1	7
2015	1	2	3
2016	5	0	5
2017	9	3	12
2018	4	1	5
2019	3	2	5
2020	2	1	3
2021	5	0	5
2022	7	0	7
2023	2	0	2
2024	3	1	4

Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.

Bao A, Karalis DG. Statin Therapy for Primary and Secondary Prevention in Older Adults. Curr Atheroscler Rep. 2024 Nov 25; 27(1):11.

View in: PubMed
Zac-Varghese S, Mark P, Bain S, Banerjee D, Chowdhury TA, Dasgupta I, De P, Fogarty D, Frankel A, Goldet G, Karalliedde J, Mallik R, Montero R, Sharif A, Wahba M, Dhatariya K, McCafferty K, Lioudaki E, Winocour P. Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024. BMC Nephrol. 2024 Jul 06; 25(1):216.

View in: PubMed
Dos Santos DZ, Elbaz M, Branchard E, Schormann W, Brown CE, Meek AR, Njar VCO, Hamilton RJ, Reed MA, Andrews DW, Penn LZ. Sterol-like drugs potentiate statin-triggered prostate cancer cell death by inhibiting SREBP2 nuclear translocation. Biomed Pharmacother. 2024 Aug; 177:116934.

View in: PubMed
Fares J, Summer R, Loizidis G. Letter to the editor in response to article "Use of statins in patients with established idiopathic inflammatory myopathies". Clin Rheumatol. 2024 Jul; 43(7):2371.

View in: PubMed
Musmar B, Spellicy S, Salim H, Abdelgadir J, Zomorodi A, Cutler A, Jabbour P, Hasan D. Comparative outcomes of middle meningeal artery embolization with statins versus embolization alone in the treatment of chronic subdural hematoma: a systematic review and meta-analysis. Neurosurg Rev. 2023 Oct 03; 46(1):262.

View in: PubMed
Hlatky MA, Gonzalez PE, Manson JE, Buring JE, Lee IM, Cook NR, Mora S, Bubes V, Stone NJ. Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo. JAMA Cardiol. 2023 Jan 01; 8(1):74-80.

View in: PubMed
Weight N, Moledina S, Zoccai GB, Zaman S, Smith T, Siller-Matula J, Dafaalla M, Rashid M, Nolan J, Mamas MA. Impact of pre-existing vascular disease on clinical outcomes. Eur Heart J Qual Care Clin Outcomes. 2022 Dec 13; 9(1):64-75.

View in: PubMed
Laffin LJ, Bruemmer D, Garcia M, Brennan DM, McErlean E, Jacoby DS, Michos ED, Ridker PM, Wang TY, Watson KE, Hutchinson HG, Nissen SE. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory?Biomarkers. J Am Coll Cardiol. 2023 01 03; 81(1):1-12.

View in: PubMed
Desai NR, Farbaniec M, Karalis DG. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clin Cardiol. 2023 Jan; 46(1):13-21.

View in: PubMed
Rossini E, Biscetti F, Rando MM, Nardella E, Cecchini AL, Nicolazzi MA, Covino M, Gasbarrini A, Massetti M, Flex A. Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter? Int J Mol Sci. 2022 Aug 18; 23(16).

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement